[go: up one dir, main page]

MA29458B1 - Composition de vaccin - Google Patents

Composition de vaccin

Info

Publication number
MA29458B1
MA29458B1 MA30386A MA30386A MA29458B1 MA 29458 B1 MA29458 B1 MA 29458B1 MA 30386 A MA30386 A MA 30386A MA 30386 A MA30386 A MA 30386A MA 29458 B1 MA29458 B1 MA 29458B1
Authority
MA
Morocco
Prior art keywords
vectors
adenoviruses
adenovirus
hiv
virus
Prior art date
Application number
MA30386A
Other languages
English (en)
Inventor
Peter Franz Ertl
John Philip Tite
Wely Catherine Ann Van
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36954770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29458(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA29458B1 publication Critical patent/MA29458B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PRÉSENTE INVENTION PORTE SUR DES VECTEURS DE VIRUS COMPRENANT DES OLIGONUCLÉOTIDES CODANT DES POLYPEPTIDES VIH ET PLUS PARTICULIÈREMENT SUR UN VECTEUR DE VIRUS QUI EST UN ADÉNOVIRUS. CES ADÉNOVIRUS SONT EN PARTICULIER DES ADÉNOVIRUS DE PRIMATES NON HUMAINS TELS QUE DES ADÉNOVIRUS DE SINGES, PLUS PRÉCISÉMENT DES ADÉNOVIRUS DE CHIMPANZÉS. CETTE INVENTION CONCERNE EN PARTICULIER DES VECTEURS D'ADÉNOVIRUS QUI COMPRENNENT DES SÉQUENCES DE POLYNUCLÉOTIDES VIH QUI CODENT DE MULTIPLES ANTIGÈNES VIH DIFFÉRENTS, PAR EXEMPLE AU MOINS DEUX OU TROIS ANTIGÈNES VIH. CETTE INVENTION CONCERNE ÉGALEMENT DES MÉTHODES DE PRÉPARATION DES VECTEURS DE VIRUS, LES VECTEURS DE VIRUS PRODUITS PAR CES MÉTHODES ET L'UTILISATION DE CES VECTEURS EN MÉDECINE, EN PARTICULIER DANS LA VACCINATION PROPHYLACTIQUE OU THÉRAPEUTIQUE.
MA30386A 2005-05-12 2007-11-20 Composition de vaccin MA29458B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68038905P 2005-05-12 2005-05-12

Publications (1)

Publication Number Publication Date
MA29458B1 true MA29458B1 (fr) 2008-05-02

Family

ID=36954770

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30386A MA29458B1 (fr) 2005-05-12 2007-11-20 Composition de vaccin

Country Status (20)

Country Link
US (1) US20090208515A1 (fr)
EP (1) EP1880012B1 (fr)
JP (2) JP5175178B2 (fr)
KR (1) KR101451620B1 (fr)
CN (2) CN103088060A (fr)
AR (1) AR053275A1 (fr)
AU (1) AU2006245920A1 (fr)
BR (1) BRPI0608798A2 (fr)
CA (1) CA2608316A1 (fr)
EA (1) EA200702190A1 (fr)
ES (1) ES2546330T3 (fr)
IL (1) IL186828A (fr)
MA (1) MA29458B1 (fr)
MX (1) MX2007014038A (fr)
NO (1) NO20075648L (fr)
PE (1) PE20061372A1 (fr)
SG (1) SG182173A1 (fr)
TW (1) TW200716750A (fr)
WO (1) WO2006120034A1 (fr)
ZA (1) ZA200709518B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230488B1 (hu) 2001-11-21 2016-08-29 The Trustees Of The University Of Pennsylvania Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására
US20090246220A1 (en) 2006-08-28 2009-10-01 Ertl Hildegund C J Constructs for enhancing immune responses
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
CN101675068A (zh) * 2007-03-02 2010-03-17 葛兰素史密丝克莱恩生物有限公司 新的方法和组合物
ES2607029T3 (es) 2007-11-28 2017-03-28 The Trustees Of The University Of Pennsylvania Adenovirus que comprende una proteína hexónica de la cápside del adenovirus E de simio SAdV-39 y usos de la misma
ES2621165T3 (es) * 2007-11-28 2017-07-03 The Trustees Of The University Of Pennsylvania Adenovirus de simio de la subfamilia B SADV-28, -27, -29, -32, -33 y -35 y usos de los mismos
JP5661476B2 (ja) 2008-03-04 2015-01-28 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア サルアデノウイルスＳＡｄＶ−３６、−４２．１、−４２．２および−４４ならびにそれらの用途
CN105709221B (zh) 2011-04-06 2020-11-17 拜欧瓦克西姆有限公司 用于预防和/或治疗人中的hiv疾病的药物组合物
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
PL2825640T3 (pl) 2012-03-12 2016-10-31 Partie rekombinowanych adenowirusów o zmienionych końcach
EP2850194A4 (fr) 2012-05-18 2016-06-08 Univ Pennsylvania Adénovirus simiens de la sous-famille e a1302, a1320, a1331 et a1337 et leurs utilisations
US9624510B2 (en) 2013-03-01 2017-04-18 The Wistar Institute Adenoviral vectors comprising partial deletions of E3
CN111499733A (zh) * 2013-03-14 2020-08-07 美国安进公司 三型金属蛋白酶（timp-3）组织抑制剂的变体、组合物和方法
ES2836432T3 (es) 2015-03-18 2021-06-25 Janssen Vaccines & Prevention Bv Ensayos para sistemas de expresión recombinante
CA2981841A1 (fr) 2015-04-14 2016-10-20 Janssen Vaccines & Prevention B.V. Adenovirus recombine exprimant deux transgenes avec un promoteur bidirectionnel
MX2017016105A (es) * 2015-06-12 2018-05-15 Glaxosmithkline Biologicals Sa Polinucleotidos y polipeptidos de adenovirus.
WO2017011336A1 (fr) 2015-07-10 2017-01-19 E.&J. Gallo Winery Système et procédé de distribution d'une boisson
RU2758238C2 (ru) 2016-05-12 2021-10-26 Янссен Вэксинс Энд Превеншн Б.В. Эффективный и сбалансированный двунаправленный промотор
CN109312362B (zh) 2016-06-20 2022-06-28 扬森疫苗与预防公司 有效和平衡的双向启动子
WO2018026547A1 (fr) 2016-08-01 2018-02-08 The Wistar Institute Of Anatomy And Biology Compositions et procédés de vecteurs adénoviraux à réplication déficiente pour des applications de vaccin
KR102111244B1 (ko) 2017-02-09 2020-05-15 얀센 백신스 앤드 프리벤션 비.브이. 이종 유전자의 발현을 위한 강력한 짧은 프로모터

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010087A1 (fr) * 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Vecteurs d'adenovirus de chimpanze
US6733993B2 (en) * 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
WO2002022080A2 (fr) * 2000-09-15 2002-03-21 Merck & Co., Inc. Vaccins adenoviraux de premiere generation evolues, exprimant les proteines gag, pol et nef du vih-1 a optimisation des codons et leurs modifications
KR20040043129A (ko) * 2001-06-22 2004-05-22 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 세포독성 면역 반응을 유도하는 방법과 그에 유용한재조합체 원숭이 아데노바이러스 조성물
MXPA04002631A (es) * 2001-09-20 2004-07-08 Glaxo Group Ltd Vacunas de adn optimizadas por codon gag-vih.
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
GB0225786D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
CA2539864A1 (fr) * 2003-09-24 2005-04-07 Oxxon Therapeutics Limited Vaccins pharmaceutiques contre le vih
GB2406336A (en) * 2003-09-24 2005-03-30 Oxxon Pharmaccines Ltd HIV Pharmaccines
GB0417494D0 (en) * 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine

Also Published As

Publication number Publication date
MX2007014038A (es) 2008-02-11
EP1880012B1 (fr) 2015-07-08
KR101451620B1 (ko) 2014-10-21
SG182173A1 (en) 2012-07-30
IL186828A0 (en) 2008-02-09
ES2546330T3 (es) 2015-09-22
KR20080021659A (ko) 2008-03-07
AR053275A1 (es) 2007-04-25
JP2008539746A (ja) 2008-11-20
BRPI0608798A2 (pt) 2011-03-15
WO2006120034A8 (fr) 2007-11-15
JP5175178B2 (ja) 2013-04-03
IL186828A (en) 2015-06-30
US20090208515A1 (en) 2009-08-20
AU2006245920A1 (en) 2006-11-16
CA2608316A1 (fr) 2006-11-16
EP1880012A1 (fr) 2008-01-23
CN103088060A (zh) 2013-05-08
ZA200709518B (en) 2014-01-29
CN101384722A (zh) 2009-03-11
EA200702190A1 (ru) 2008-04-28
WO2006120034A1 (fr) 2006-11-16
TW200716750A (en) 2007-05-01
NO20075648L (no) 2008-02-07
JP2013046613A (ja) 2013-03-07
PE20061372A1 (es) 2007-01-16

Similar Documents

Publication Publication Date Title
MA29458B1 (fr) Composition de vaccin
NO20035740D0 (no) Fremgangsmåter for å indusere en cytotoksisk immunrespons og rekombinante ape-adenovirussammensetninger nyttige for disse
NL300897I2 (nl) Neisseira meningitidis serogroep B recombinant gelipideerd fHbp subfamilie A05 eiwit
HUP0303720A2 (hu) Egy immunstimuláns oligonukleotidot és egy tokolt tartalmazó adjuvánskészítmény
MA30250B1 (fr) Vaccins destines a lutter contre une infection a chlamydia
HK1052301A1 (zh) α(2)巨球蛋白与抗原分子的复合物作免疫治疗用途
HUP0401591A2 (hu) Új receptor-nukleinsavak és- polipeptidek
MXPA05011110A (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos.
MA30670B1 (fr) Vaccins contre le paludisme
BRPI0415699A (pt) uso de oligossacarìdeo ácido e de oligossacarìdeo neutro, e, composições alimentìcia e lìquida
PT1154790E (pt) Reforco da actividade bactericida de antigenios contra a neisseria com oligonucleotidos contendo motivos cg
EA200600403A1 (ru) Препараты кладрибина для улучшенной пероральной доставки и доставки через слизистые оболочки
MA32030B1 (fr) Vaccins anti-malaria
BR0109502A (pt) Molécula de interesse farmacêutico, composição farmacêutica, vacina, método de diagnóstico in vitro de patologias associadas com a presença em um corpo de paciente de ligandos do mhc, pacote ou kit para execução de métodos de diagnóstico in vitro, utilizações de um ligando e de um ácido forte, e, processo de preparação e de estabilização de uma molécula de interesse farmacêutico
MY134019A (en) Aryl oxime-piperazines useful as ccr5 antagonists
WO2004110373A3 (fr) Compositions vaccinales therapeutiques servant a traiter le diabete de type 1
MXPA04001986A (es) Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
BRPI0414073A (pt) método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
Desai et al. Platform switching: A panacea for bone loss??
DK1449535T3 (da) Præparater der omfatter fötalt hæmoglobin og bakterieendotoksin samt eventuelt fötale leverbestanddele
MA32080B1 (fr) Vaccin comprenant un extrait de protéine ribosomale (rpe) et facultativement un adjuvant promouvant la réponse th1
FR2809960B1 (fr) Composition adjuvante de la reponse immunitaire comprenant la proteine fha ou un fragment de la proteine fha sous forme libre, et composition immunogene ou vaccinale contenant une telle composition adjuvante
Benko Winning alternative.
WO2003104260A3 (fr) Formulation pharmaceutique
Greenfeld Legal Tender.